Atrial Fibrillation Clinical Trial
Official title:
A Clinical Feasibility Study to Evaluate the Safety and Performance of Low-Energy Therapy in Patients With Atrial Fibrillation Energy Therapy in Patients With Atrial Fibrillation
NCT number | NCT04206917 |
Other study ID # | CL007 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | March 19, 2020 |
Est. completion date | June 21, 2022 |
Verified date | October 2022 |
Source | Cardialen, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Assess the clinical safety and feasibility of MultiPulse Therapy (MPT) electrical stimulation waveform sequence in terminating paroxysmal and persistent atrial fibrillation.
Status | Terminated |
Enrollment | 30 |
Est. completion date | June 21, 2022 |
Est. primary completion date | June 21, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Male or female between 18 and 80 years of age 2. Willing and able to comply with the study protocol, provide a written informed consent 3. Currently indicated for atrial catheter ablation due to paroxysmal or early persistent atrial fibrillation 4. Current treatment and compliance with standard anticoagulation regimen, including uninterrupted OAC, with acceptable coagulation status, as determined by globally accepted risk stratification (CHA2DS2-VASc score) and the Principal Investigator Exclusion Criteria: 1. Life expectancy of 1 year or less 2. AF due to reversible causes (e.g., hyperthyroidism, valve disease) 3. History of DC Cardioversion which failed to convert to AF to Normal Sinus Rhythm 4. Currently in AF for more than 3 months continuously 5. Chronic, long-standing persistent, or permanent atrial fibrillation 6. Allergy or contraindication to anticoagulation therapy 7. Presence of intracardiac thrombus (confirmed with TEE or ICE) 8. Existing Left Atrial Appendage closure device 9. Severely Dilated Left Atrium >5cm 10. LVEF<20% 11. NYHA Class IV heart failure at the time of enrollment 12. History of embolic stroke, Transient Ischemic Attack (TIA) or other thromboembolic event within the preceding 3 months. 13. Known hyper-coagulable state that increases risk of thrombus 14. History of myocardial infarction or coronary revascularization within the preceding 3 months. 15. History of sustained ventricular arrhythmia or cardiac arrest 16. Presence of chronically implanted lead in the CS 17. Presence of ventricular assist device, including intra-aortic balloon pump 18. Documented bradycardia (<40 BPM) at the time of the study 19. Morbid obesity: BMI>39 kg/m2 20. Presence of any prosthetic cardiac valve 21. History of significant tricuspid valvular disease requiring surgery 22. Moderate to severe mitral valve regurgitation (>40% regurgitation fraction) 23. Cognitive or mental health status that would interfere with study participation and proper informed consent 24. Cardiovascular anatomical defects that would complicate placement of the stimulation leads required by the protocol, including congenital heart disease and cardiac vein anomalies per the Investigator's discretion 25. Pregnancy confirmed by test within 7 days of procedure. 26. Inability to pass catheters to heart due to vascular limitations 27. Cardiovascular surgery or intervention within 1 month prior to enrollment or planned for up to 1 month after enrollment (other than the planned treatment procedure) 28. No active endocarditis 29. Any other medical condition which may affect the outcome of this study or safety of the subject as determined by the investigator 30. History of hemodynamic compromise due to valvular heart disease 31. Unstable CAD as determined by the investigator 32. Severe proximal three-vessel or left main coronary artery disease without revascularization as determined by the investigators 33. History of Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Congenital Heart Anomaly, Cardiac Amyloidosis or Cardiac Sarcoidosis 34. Any other condition which may affect the outcome of this study or safety of the subject as determined by the investigator |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Adelaide Hospital | Adelaide | South Australia |
Australia | St. Andrews | Adelaide | South Australia |
Australia | The Prince Charles Hospital | Chermside | Queensland |
Australia | Gold Coast University Hospital | Gold Coast | Queensland |
Australia | Greenslopes Private Hospital | Greenslopes | Queensland |
Australia | Mulgrave Private Hospital | Melbourne | Victoria |
Lead Sponsor | Collaborator |
---|---|
Cardialen, Inc. | Avania, Iqvia Pty Ltd |
Australia,
Ambrosi CM, Ripplinger CM, Efimov IR, Fedorov VV. Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy. Heart Rhythm. 2011 Jan;8(1):101-8. doi: 10.1016/j.hrthm.2010.10.018. Epub 2010 Oct 19. — View Citation
Efimov I, Ripplinger CM. Virtual electrode hypothesis of defibrillation. Heart Rhythm. 2006 Sep;3(9):1100-2. Epub 2006 Mar 10. — View Citation
Janardhan AH, Gutbrod SR, Li W, Lang D, Schuessler RB, Efimov IR. Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. J Am Coll Cardiol. 2014 Jan 7-14;63(1):40-8. doi: 10.1016/j.jacc.2013.07.098. Epub 2013 Sep 26. — View Citation
Li W, Janardhan AH, Fedorov VV, Sha Q, Schuessler RB, Efimov IR. Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):917-25. doi: 10.1161/CIRCEP.111.965830. Epub 2011 Oct 6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To define the safety of MPT for the treatment of atrial fibrillation in subjects | Adverse Events from procedure and 30 day follow up. | Study procedure and 30 day post procedure | |
Primary | Translation | Explore and enhance MPT parameters delivered in successful cases in a previous Cardialen AF study (CL001 / NCT02257112) | Study procedure | |
Primary | Translation | Determine MPT parameters relationships at which MPT terminates AF | Study procedure | |
Primary | Translation | Determine rate of conversion from AF to NSR after MPT delivery | Study procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |